Key result
Adjunctive low-voltage zone ablation boosts 12-month atrial arrhythmia freedom by an absolute ~30% vs PVI alone.
Why the trial?
Pulmonary vein isolation alone frequently fails in persistent atrial fibrillation, and trials of additional substrate ablation have conflicted. IDEAL-AF asked whether individualised ablation of low-voltage areas improves outcomes over standard PVI.
Does adjunctive individualized low-voltage zone ablation improve freedom from atrial arrhythmia in adult patients with persistent atrial fibrillation and significant low-voltage zones undergoing first-time ablation?
Population
209 randomized (of 936 mapped) with persistent AF + low-voltage zones ≥3.0 cm²
Comparison
PVI + individualized low-voltage-zone ablation vs PVI alone
Design
Multicenter randomized clinical trial at 5 Swedish ablation centres
Follow-up
12 months
Authors
No takes yet. Share an insight, caveat, or question.
Experts read IDEAL-AF as a convincing signal that substrate-guided ablation improves outcomes in persistent AF with low-voltage zones, though questions remain about how these results compare with other trials and whether they will reshape standard practice.
The reaction to IDEAL-AF is broadly positive, with clinicians calling the results an important step toward individualized, substrate-guided ablation rather than a one-size-fits-all approach. No one disputes the direction of the findings, but at least one voice questions why the PVI-alone arm performed so differently compared with another recent trial. The open question is whether these results are strong enough to move guidelines away from PVI alone as the default strategy in persistent AF with fibrotic substrate.
Multiple clinicians agreed that IDEAL-AF supports a shift toward individualized, substrate-guided ablation in persistent AF with low-voltage zones, framing it as a move away from one-size-fits-all PVI.
One expert highlighted a striking difference in arrhythmia-free rates in the PVI-alone arms between IDEAL-AF and the SUPPRESS-AF trial, raising the question of whether patient selection or procedural factors explain the gap. It also remains unclear whether these results will be sufficient to change guideline recommendations on substrate-guided ablation.
As an electrophysiologist with ties to the research community, Drca expressed pride in seeing the IDEAL-AF trial published in JAMA and praised the team behind the work.
Edgardo Alania · Aug 31 Practice take Frames the results as evidence for substrate-guided rather than one-size-fits-all ablation, noting improved arrhythmia-free survival and quality of life without more serious adverse events. X post
Zain Khalpey · HonorHealth · Aug 31 Practice take Calls IDEAL-AF an important step toward more individualized, substrate-guided ablation in persistent AF with significant low-voltage zones. X post
Supports adjunctive low-voltage ablation in persistent AF with significant zones; extends randomized evidence beyond pulmonary vein isolation alone.
| Outcome | PVI + LVZ | PVI alone |
|---|---|---|
| Freedom from atrial arrhythmia off AADs at 12 months | 69/102 (67.6%) | 40/107 (37.4%) |
| Primary · difference 30.3 pp (95% CI 17.4–43.2); OR 3.5 (2.0–6.2); p<0.001; after 1–2 procedures | ||
| Time to first recurrence after a single procedure | ||
| Secondary · HR 0.4 (95% CI 0.3–0.6; p<0.001) favoring low-voltage-zone ablation | ||
Representation
Applies only to the 22% of screened patients with low-voltage zones ≥3.0 cm² (209 of 936).
Design limitations
The primary endpoint permitted a repeat ablation within 6 months, and serious adverse event rates are described only as similar between groups with no counts reported.
Patient burden
Quality-of-life gains are stated without numeric detail.
Does adjunctive individualized low-voltage zone ablation improve freedom from atrial arrhythmia in adult patients with persistent atrial fibrillation and significant low-voltage zones undergoing first-time ablation?
Odds Ratio: 3.5 (95% CI 2–6.2)
Absolute Event Rate: 67.6% vs 37.4%
Absolute Risk Reduction: 30.3%
p-value: p=<.001
Adjunctive low-voltage zone ablation significantly improves 12-month arrhythmia-free survival compared to pulmonary vein isolation alone in patients with persistent atrial fibrillation and significant low-voltage zones.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Nordin et al. (2026) conducted an RCT in Persistent atrial fibrillation (n=209). Individualized adjunctive low-voltage zone ablation vs. No further ablation (pulmonary vein isolation alone) was evaluated on Freedom from documented atrial arrhythmia without antiarrhythmic drugs at 12 months after 1 or 2 ablation procedures within 6 months (OR 3.5, 95% CI 2.0-6.2, p=<.001). Adjunctive low-voltage zone ablation added to pulmonary vein isolation improved freedom from atrial arrhythmia compared to isolation alone (67.6% vs 37.4%; OR 3.5; 95% CI 2.0-6.2; P<.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: